Table 4.
Baseline patient characteristics in saxagliptin 5 mg long-term combination therapy trials
| SUs + saxagliptin 5 mg (n=183) | α-Gls + saxagliptin 5 mg (n=113) | Biguanides + saxagliptin 5 mg (n=116) | TZDs + saxagliptin 5 mg (n=108) | Glinides + saxagliptin 5 mg (n=57) | |
|---|---|---|---|---|---|
| Age (year) | 62.2±9.5 | 59.1±11.3 | 57.4±10.2 | 57.2±10.6 | 60.9±11.4 |
| Male, n (%) | 116 (63.7) | 75 (67.6) | 71 (61.2) | 76 (70.4) | 4 (59.6) |
| BMI (kg/m2) | 24.41±3.80 | 24.38±4.34 | 26.50±4.37 | 27.54±5.99 | 25.61±4.47 |
| Duration of T2DM (year) | 10.10±6.97 | 8.10±6.44 | 7.20±5.19 | 7.95±5.81 | 7.03±6.89 |
| HbA1c (%) | 8.46±0.72 | 8.59±0.88 | 8.50±0.81 | 8.65±0.96 | 8.22±0.67 |
| Fasting plasma glucose (mg/dL) | 162.0±33.3 | 179.6±39.2 | 168.8±35.9 | 177.9±40.7 | 159.8±30.2 |
| 1.5-AG (μU/mL) | 4.70±3.20 | 6.25±5.20 | 5.29±4.21 | 3.96±3.41 | 6.45±4.10 |
| HOMA-β (%) | 29.58±25.10 | 23.89±19.00 | 34.31±27.16 | 24.99±19.85 | 37.89±35.31 |
| HOMA-IR | 2.91±2.27 | 3.13±2.31 | 3.74±2.39 | 3.28±2.94 | 3.74±3.89 |
| Diabetic complication, n (%) | |||||
| Presence | 91 (50.0) | 49 (44.1) | 60 (51.7) | 55 (50.9) | 34 (59.6) |
| Diabetic neuropathy | 34 (18.7) | 15 (13.5) | 21 (18.1) | 18 (16.7) | 14 (24.6) |
| Diabetic retinopathy | 34 (18.7) | 13 (11.7) | 17 (14.7) | 19 (17.6) | 10 (17.5) |
| Diabetic nephropathy | 53 (29.1) | 32 (28.8) | 40 (34.5) | 35 (32.4) | 18 (31.6) |
| Others | 7 (3.8) | 0 (0.0) | 2 (1.7) | 2 (1.9) | 1 (1.8) |
| Complications of cardiovascular disease, n (%) | |||||
| Presence | 26 (14.3) | 6 (5.4) | 12 (10.3) | 11 (10.2) | 11 (19.3) |
Note: Values are mean ± SD.
Abbreviations: BMI, body mass index; T2DM, type 2 diabetes mellitus; HbA1c, glycated hemoglobin; HOMA-IR, homeostatic model insulin resistance; HOMA-β, homeostatic model assessment of β-cells; SD, standard deviation; SUs, sulfonylureas; TZDs, thiazolidinediones; α-GIs, α-glycosidase inhibitors; 1,5-AG, 1,5-anhydroglucitol.